AARP-branded UnitedHealthcare Medicare plans do not cover Wegovy when it is prescribed for weight loss alone, so the short answer to whether AARP UnitedHealthcare covers Wegovy is no for that use. Coverage is possible, though, when the drug is prescribed for an approved cardiovascular or liver indication, and a separate federal program running through December 31, 2026 gives Medicare beneficiaries a temporary way to get Wegovy for weight management at a flat $50 per month.
Why Weight-Loss Use Is Blocked
The Medicare Prescription Drug, Improvement and Modernization Act of 2003 explicitly excludes weight-loss medications from Part D coverage. Congress has not repealed that provision, and in April 2025 the Trump Administration declined to finalize a Biden-era proposed rule that would have reinterpreted the exclusion to allow coverage for beneficiaries with obesity. The statutory bar is still in place as of mid-2026.
That exclusion applies to any Part D plan, including the AARP-branded standalone Part D plans and AARP Medicare Advantage plans with drug coverage that UnitedHealthcare administers.
When AARP UnitedHealthcare Medicare Plans Will Cover Wegovy
Wegovy has FDA approvals beyond weight loss, and those uses fall outside the statutory exclusion. In March 2024 the FDA approved Wegovy to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established heart disease who are overweight or obese. CMS then confirmed that Part D plans could add Wegovy to their formularies for that cardiovascular indication.
Under UnitedHealthcare’s non-formulary Wegovy policy, effective May 2026, the insurer covers Wegovy for two medical indications: cardiovascular risk reduction and treatment of metabolic dysfunction-associated steatohepatitis (a serious liver condition). Weight loss by itself is still excluded. Because Wegovy is non-formulary, the pharmacy cannot simply fill it; the prescriber has to submit a prior authorization request.
Cardiovascular Prior Authorization Criteria
To qualify under the cardiovascular pathway, a patient must meet all of the following:
- Age 45 or older.
- BMI of at least 27 kg/m².
- A documented prior heart attack, prior stroke, or symptomatic peripheral arterial disease.
- Active use of standard heart medications (statins, antiplatelets, beta-blockers, and ACE inhibitors or equivalents), unless contraindicated.
- No diabetes diagnosis, hemoglobin A1c no higher than 6.5%, and no class IV heart failure.
Both the Wegovy injection and the oral tablet, which Novo Nordisk launched in the U.S. in early January 2026 after FDA approval in December 2025, are included in UnitedHealthcare’s prior authorization policies for these medical indications.
The Medicare GLP-1 Bridge for Weight Management
If the reason for the prescription is weight management rather than heart disease or liver disease, the only Medicare-connected option as of mid-2026 is the Medicare GLP-1 Bridge. It launched on July 1, 2026 and runs through at least December 31, 2026. The Bridge sits entirely outside the standard Part D benefit, which is why the statutory weight-loss exclusion does not block it.
Beneficiaries in any standalone Part D plan or Medicare Advantage plan with drug coverage are eligible, including those enrolled in AARP-branded plans administered by UnitedHealthcare. The AARP plan itself does not need to opt in. The Bridge runs through a separate central processor managed by Humana on behalf of CMS.
How to Use It
The prescribing doctor submits the prior authorization request directly to the central processor, not to UnitedHealthcare. No Part D denial is required first. The doctor must attest that the patient is at least 18 and meets one of three BMI-based tiers:
- BMI of 35 or higher, with no additional condition required.
- BMI of 30 or higher with a comorbidity such as heart failure, uncontrolled high blood pressure, or chronic kidney disease.
- BMI of 27 or higher with prediabetes or established cardiovascular disease.
Once approved, the beneficiary pays a flat $50 copay per month at the pharmacy. The pharmacy routes the claim through a designated Bridge routing number rather than the member’s AARP Part D plan. Covered drugs include both the Wegovy injection and the oral tablet, as well as the KwikPen formulation of Zepbound and a newer pill called Foundayo.
One Important Catch
The $50 monthly copay does not count toward the Part D out-of-pocket maximum or deductible. It sits completely outside the regular Part D benefit, so it will not help a beneficiary reach catastrophic coverage on their AARP plan.
What Happens in 2027
The Bridge was designed as a short-term measure while CMS prepared a longer-term program called the BALANCE Model, which was intended to let Part D plans voluntarily cover GLP-1 drugs for obesity starting in January 2027. Under BALANCE, participating manufacturers agreed to a net price of $245 per monthly supply, and beneficiaries in enhanced Part D plans would pay $50 per month.
BALANCE’s launch depends on at least 80% of Part D plan sponsors agreeing to participate. That threshold was due to be assessed by April 30, 2026, but as of mid-2026 CMS has not confirmed whether it was met. An Optum Advisory executive quoted in reporting on the matter said most Part D plan sponsors do not believe the 80% threshold will be reached, and the Medicare portion of BALANCE has been described as “delayed indefinitely.” CMS has said only that it will share next steps when available.
If BALANCE does not launch and the Bridge is not extended, beneficiaries who got Wegovy through the Bridge in 2026 could lose that access in 2027.
Price is moving in a different direction. CMS selected Wegovy, Ozempic, and Rybelsus for the second round of Inflation Reduction Act price negotiations, with results announced in November 2025. The negotiated maximum fair price for Wegovy is $385.63 for a 30-day supply of the 2.4 mg injection, effective January 1, 2027. Novo Nordisk also agreed to a most-favored-nation price of $245 per monthly supply for all semaglutide products starting in 2026 under a separate White House deal. Wegovy’s retail price without any discount is roughly $1,300 per month. These lower prices reduce out-of-pocket costs for beneficiaries who do have coverage through one of the pathways above; they do not change whether coverage exists.
If You Have AARP Medigap Instead
AARP Medigap (Medicare supplement) plans and AARP Medicare Advantage plans are easy to confuse, and they work very differently for drugs. Medigap plans do not include prescription drug coverage at all. A beneficiary with original Medicare and an AARP Medigap policy who wants drug coverage has to enroll in a separate standalone Part D plan, and that Part D plan is subject to the same rules described above: no coverage for weight loss, possible coverage for cardiovascular or liver indications with prior authorization, and access to the Bridge program on the same terms as any other Part D enrollee.
AARP Medicare Advantage plans typically bundle hospital, medical, and prescription drug coverage into a single plan. For those plans, whether Wegovy is available depends on the plan’s formulary and prior authorization requirements, which follow UnitedHealthcare’s policies for the specific medical indication.